Treatment Resistant Depression Market To Reach Worth US$ 1,129.1 Bn By 2024: Selective Serotonin Reuptake Inhibitors To Continue To Dominate The Market

According to the latest report published by Credence Research, Inc. “Treatment Resistant Depression Market: Growth, Future Prospects and Competitive Analysis, 2016-2024,” the  treatment resistant depression market was valued at US$ 863.9  Mn in 2015, and is expected to reach US$ 1,129.1 Mn by 2024, expanding at a CAGR of 3% from 2016 to 2024.

Browse the full report Treatment Resistant Depression Market: Growth, Future Prospects and Competitive Analysis, 2016-2024 report at http://www.credenceresearch.com/report/treatment-resistant-depression-market

Market Insights

Depression is among the most common mental disorders worldwide, affecting approximately 6.7% individuals in the U.S. alone, each year (Anxiety and Depression Association of America). This condition also creates a significant economic burden on the healthcare system. Patients diagnosed with treatment resistant depression has failed two or more antidepressant therapies. Such patients present a critical therapeutic challenge to mental health as this patient group requires specialized TRD management.

The prevalence of treatment resistant depression is substantial in several European and American countries and peaks in the 40 to 60 age group. Females present a substantially high disease burden, accounting to almost twice as their male counterparts. As opined by treatment providers, patients with TRD are found to be twice as likely as those with major depressive disorder to be hospitalized, thus adding to healthcare cost burden for hospitalized treatment resistant depression patients by 5 to 6 times. Therefore, TRD is a major and the most neglected public health issue with an estimated 12 month prevalence of 2% to 3% for Stage 1 TRD and 1.5% to 2% for Stage 2 TRD.

Download sample research report @ https://www.credenceresearch.com/sample-request/58359

1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offering
1.2. Research Scope
1.3. Research Methodology
1.3.1. Research Methodology
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Assumptions

2. Executive Summary
2.1. Global Treatment Resistant Depression Market Portraiture
2.2. Global Treatment Resistant Depression, by Drug Type, 2015 & 2024 (Value %)
2.3. Global Treatment Resistant Depression, by Geography, 2015 (Value %)

3. Treatment Resistant Depression Market: Market Dynamics and Future Outlook 
3.1. Global Treatment Resistant Depression Market Overview
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.1.1. Increasing prevalence of anxiety and depression related disorders in young adults
3.2.1.2. Rise in geriatric population
3.2.2. Challenges
3.2.2.1. Patent expiry of major antidepressants …

6. Profiles
6.1. AstraZeneca plc
6.1.1. Business Description
6.1.2. Financial Information
6.1.3. Product Positions/Portfolio
6.1.4. News Coverage
6.2. Bristol-Myers Squibb
6.3. Eli Lilly and Company
6.4. Forest Laboratories (Allergan plc)
6.5. GlaxoSmithKline plc …

Request for customization research report @ https://www.credenceresearch.com/request-for-customization/58359

About Robson

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.

View all posts by Robson →